# Osivax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/osivax

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.osivax.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Mar 15, 2019)
- Investors on record: 4

## About

Based in France, Osivax SAS is a biotechnology company focused on developing innovative universal vaccines to combat highly mutating viruses, particularly influenza and coronaviruses.Founded in 2017 and headquartered in Lyon, France, Osivax SAS specializes in biotechnology aimed at vaccine development. The company was founded by Alexandre Le Vert, who has a background in biotech ventures. In March 2025, Osivax raised EUR 10 million in a Series B funding round, marking their continued growth and commitment to developing their vaccine candidates, including OVX836, which has advanced through early clinical trials.Osivax specializes in developing a new class of universal vaccines aimed at providing long-term protection against highly mutating viruses. Their core technology, oligoDOM, utilizes self-assembling nanoparticles designed to elicit strong T-cell immune responses against conserved internal antigens of viruses. This technology is particularly beneficial for addressing the challenges posed by rapidly evolving influenza and coronavirus strains. The flagship product, OVX836, has progressed through Phase 1 and Phase 2a clinical trials, demonstrating a solid safety profile and promising efficacy signals. Osivax primarily serves global health markets, focusing on both public health organizations and private healthcare providers, with ongoing efforts to expand its reach to other infectious diseases beyond influenza and coronaviruses.Osivax reported a revenue of EUR 91,074.40 in 2018, with an EBITDA of EUR -2,225,236.40 for the same year. The company's revenue model centers around strategic partnerships and collaborations with governmental health agencies, research institutions, and pharmaceutical companies, involving funding arrangements for clinical trials and commercialization agreements for their vaccine candidates.In March 2025, Osivax SAS secured EUR 10 million in Series B funding to finance clinical pre-trials and studies for OVX836, their influenza vaccine. The company aims to enhance its product offerings and is targeting expansion into new markets, with specific plans to broaden its reach in the global healthcare sector. These initiatives will be supported by the recent funding, which is pivotal for advancing their clinical development efforts.

## Funding rounds

- Series A, Mar 15, 2019, $3.5M — Pradeyrol Développement, Noshaq, Anaxago, Notus Technologies

## Investors

- Pradeyrol Développement — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- Anaxago — Series A
- Notus Technologies (https://capitalatlas.ai/funds/notus-technologies) — Series A